Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM-1 (orbetinib fumarate) in advanced triple-negative breast cancer
CTR20223140Phase 2Active
- Sponsor
- Shenzhen Zhenxing Pharmaceutical Technology
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SM-1 in triple-negative breast cancer (TNBC), sponsored by Shenzhen Zhenxing Pharmaceutical Technology. Primary endpoint: Disease Control Rate (DCR). Started Apr 2023; status: active.
02
Drugs
SM-1
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20223140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223140.